Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide Combined With AK112 for Advanced Bone and Soft Tissue Sarcoma
NCT06637007Phase 2Recruiting
- Sponsor
- Shanxi Cancer Hospital
- Start
- Aug 2024
- Primary completion
- Dec 2024
- Modality
- Antibody Conjugates, Small Molecules, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab, tucidinostat in soft tissue sarcoma (STS), bone sarcoma, sponsored by Shanxi Cancer Hospital. Started Aug 2024; status: recruiting.
02
Drugs
ivonescimabtucidinostat
03
Conditions
soft tissue sarcoma (STS)bone sarcoma
Beyond the preview
Go deeper on NCT06637007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06637007.